When General Counsel Jeffrey Plumer first joined Evolus Inc. in what was his first in-house gig, he saw the job as an opportunity to expand his legal skillset in areas such as compliance, international contracts, product licensing and acquisitions.
Since 2014, Plumer has seen the medical aesthetics firm through its initial public offering in 2018, the launch of its flagship neurotoxin product – not without some complications on the way—and its first-ever operating profit ahead of schedule (Nasdaq: EOLS).
Plumer was vice president of legal and corporate secretary at Evolus for six years until 2020, when he was appointed general counsel. Now he oversees all legal and compliance matters for the Newport Beach company.
After Plumer won at the Business Journal’s General Counsel Awards in 2024, he said that each moment of growth gave him a new toolkit.
“Whether it’s a crisis, whether it’s hard times or even some of the great times,” he told the Business Journal.
Last year, Plumer said Evolus was a public company on the brink of a new part of the medical industry since he was in the middle of studying a different layer of regulation related to medical devices instead of pharmaceuticals.
New Products
This year, the firm launched Evolysse Form and Evolysse Smooth, which refers to its injectable hyaluronic acid gels.
The first two products in the Evolysse collection received Food and Drug Administration (FDA) approval in February.
It is the second addition to Evolus’ product portfolio, following its first aesthetic neurotoxin product Jeuveau—an injection used to improve the appearance of frown lines between the eyebrows.
In 2023, Plumer negotiated with French company Symatese Aesthetics the licensing deal for Evolus to be the exclusive U.S. distributor of the Evolysse line of five dermal fillers.
Following the new product’s release in June, Chief Executive David Moatazedi said that Evolysse was outperforming the initial launch of Jeuveau and that it was “proving to be a powerful complement” in its portfolio.
Evolus also received Medical Device Regulation approval in Europe for four unique injectable hyaluronic gels under the brand name Estyme, expanding its presence into the global dermal filler market.
It plans to do a limited rollout of Estyme to select physicians with a broader European launch on track for the second half of 2025, according to the company.
Evolus anticipates Evolysse and Estyme to contribute between 8% to 10% of total sales for 2025.
The local aesthetics firm also partnered with Symatese to begin the commercial launch of Nuceiva in France this year after winning approval from the European Commission.
In August, Evolus reported second quarter results that “came in below expectations, reflecting one of the most challenging market environments we’ve seen in recent years,” CEO Moatazedi said in an Aug. 5 earnings call.
Saying demand has weakened within the U.S. aesthetics market, the company slashed its 2025 full-year revenue guidance to $295 million to $305 million from an April forecast of $345 million to $355 million.
At press time, Evolus had a market cap of $398 million with shares trading around $6.15 apiece—down about 44% year-to-date.
